Cargando…
Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever
BACKGROUND: Children with febrile neutropenia commonly exhibit alterations of pharmacokinetic (PK) parameters, leading to decreased β‐lactam concentrations. AIMS: This study evaluated piperacillin PK and probability of target attainment (PTA) with continuous infusion of piperacillin‐tazobactam, in o...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575485/ https://www.ncbi.nlm.nih.gov/pubmed/34796702 http://dx.doi.org/10.1002/cnr2.1585 |
_version_ | 1784811325489152000 |
---|---|
author | Maarbjerg, Sabine F. Thorsted, Anders Friberg, Lena E. Nielsen, Elisabet I. Wang, Mikala Schrøder, Henrik Albertsen, Birgitte K. |
author_facet | Maarbjerg, Sabine F. Thorsted, Anders Friberg, Lena E. Nielsen, Elisabet I. Wang, Mikala Schrøder, Henrik Albertsen, Birgitte K. |
author_sort | Maarbjerg, Sabine F. |
collection | PubMed |
description | BACKGROUND: Children with febrile neutropenia commonly exhibit alterations of pharmacokinetic (PK) parameters, leading to decreased β‐lactam concentrations. AIMS: This study evaluated piperacillin PK and probability of target attainment (PTA) with continuous infusion of piperacillin‐tazobactam, in order to optimize the dosing regimen. METHODS: This prospective PK study included children with cancer, aged 1–17 years, who were treated with piperacillin‐tazobactam for suspected or verified infection. A piperacillin‐tazobactam loading dose (100 mg/kg) was administered followed by continuous infusion (300 mg/kg/day). The unbound fraction of piperacillin was quantified by high‐performance liquid chromatography and PK were described using population PK modeling. PK data was used to update and extend a previous PK model built on data following intermittent administration. Monte Carlo simulations were performed to assess PTA for targets of 100% time above the minimum inhibitory concentration (100% fT > MIC) and 50% fT > 4xMIC. RESULTS: We included 68 fever episodes among 38 children with a median (IQR) age of 6.5 years and body weight of 27.4 kg (15.1–54.0). A three‐compartment model adequately described the concentration‐time data. Median (95% confidence interval) estimates for clearance and piperacillin concentration at steady state were 14.2 L/h/70 kg (13.0; 15.3) and 47.6 mg/L (17.2; 129.5), respectively. Body weight or lean body weight was significantly associated with the PK parameters, and body weight was integrated in the final PK model. Based on piperacillin exposure, continuous infusion was the only dosing regimen to achieve optimal PTA for the P. aeruginosa breakpoint (16 mg/L) with the target of 100% fT > MIC, and a daily dose of 300 mg/kg reached optimal PTA. The strict target of 50% fT > 4xMIC (64 mg/L) was not feasibly attained by any dosing regimen at recommended doses. CONCLUSION: Unlike conventional piperacillin intermittent administration and extended infusion regimens, continuous infusion allows the target of 100% fT > MIC to be reached for children with febrile neutropenia. |
format | Online Article Text |
id | pubmed-9575485 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95754852022-10-18 Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever Maarbjerg, Sabine F. Thorsted, Anders Friberg, Lena E. Nielsen, Elisabet I. Wang, Mikala Schrøder, Henrik Albertsen, Birgitte K. Cancer Rep (Hoboken) Original Articles BACKGROUND: Children with febrile neutropenia commonly exhibit alterations of pharmacokinetic (PK) parameters, leading to decreased β‐lactam concentrations. AIMS: This study evaluated piperacillin PK and probability of target attainment (PTA) with continuous infusion of piperacillin‐tazobactam, in order to optimize the dosing regimen. METHODS: This prospective PK study included children with cancer, aged 1–17 years, who were treated with piperacillin‐tazobactam for suspected or verified infection. A piperacillin‐tazobactam loading dose (100 mg/kg) was administered followed by continuous infusion (300 mg/kg/day). The unbound fraction of piperacillin was quantified by high‐performance liquid chromatography and PK were described using population PK modeling. PK data was used to update and extend a previous PK model built on data following intermittent administration. Monte Carlo simulations were performed to assess PTA for targets of 100% time above the minimum inhibitory concentration (100% fT > MIC) and 50% fT > 4xMIC. RESULTS: We included 68 fever episodes among 38 children with a median (IQR) age of 6.5 years and body weight of 27.4 kg (15.1–54.0). A three‐compartment model adequately described the concentration‐time data. Median (95% confidence interval) estimates for clearance and piperacillin concentration at steady state were 14.2 L/h/70 kg (13.0; 15.3) and 47.6 mg/L (17.2; 129.5), respectively. Body weight or lean body weight was significantly associated with the PK parameters, and body weight was integrated in the final PK model. Based on piperacillin exposure, continuous infusion was the only dosing regimen to achieve optimal PTA for the P. aeruginosa breakpoint (16 mg/L) with the target of 100% fT > MIC, and a daily dose of 300 mg/kg reached optimal PTA. The strict target of 50% fT > 4xMIC (64 mg/L) was not feasibly attained by any dosing regimen at recommended doses. CONCLUSION: Unlike conventional piperacillin intermittent administration and extended infusion regimens, continuous infusion allows the target of 100% fT > MIC to be reached for children with febrile neutropenia. John Wiley and Sons Inc. 2021-11-18 /pmc/articles/PMC9575485/ /pubmed/34796702 http://dx.doi.org/10.1002/cnr2.1585 Text en © 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Maarbjerg, Sabine F. Thorsted, Anders Friberg, Lena E. Nielsen, Elisabet I. Wang, Mikala Schrøder, Henrik Albertsen, Birgitte K. Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever |
title | Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever |
title_full | Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever |
title_fullStr | Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever |
title_full_unstemmed | Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever |
title_short | Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever |
title_sort | continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575485/ https://www.ncbi.nlm.nih.gov/pubmed/34796702 http://dx.doi.org/10.1002/cnr2.1585 |
work_keys_str_mv | AT maarbjergsabinef continuousinfusionofpiperacillintazobactamsignificantlyimprovestargetattainmentinchildrenwithcancerandfever AT thorstedanders continuousinfusionofpiperacillintazobactamsignificantlyimprovestargetattainmentinchildrenwithcancerandfever AT friberglenae continuousinfusionofpiperacillintazobactamsignificantlyimprovestargetattainmentinchildrenwithcancerandfever AT nielsenelisabeti continuousinfusionofpiperacillintazobactamsignificantlyimprovestargetattainmentinchildrenwithcancerandfever AT wangmikala continuousinfusionofpiperacillintazobactamsignificantlyimprovestargetattainmentinchildrenwithcancerandfever AT schrøderhenrik continuousinfusionofpiperacillintazobactamsignificantlyimprovestargetattainmentinchildrenwithcancerandfever AT albertsenbirgittek continuousinfusionofpiperacillintazobactamsignificantlyimprovestargetattainmentinchildrenwithcancerandfever |